𝔖 Bobbio Scriptorium
✦   LIBER   ✦

N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome

✍ Scribed by Susumu Kusunoki; Atsuro Chiba; Kazuo Kon; Susumu Ando; Kazuko Arisawa; Asako Tate; Ichiro Kanazawa

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
649 KB
Volume
35
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

✦ Synopsis

Serum antibodies against such major glycolipids as GMI, GDlb, and LM1 have been reported in patients in the acute phase of Guillain-Barre syndrome (GBS). Because minor unidentified glycolipids also may be targets of antibodies in GBS sera, we assayed serum antibody against a crude ganglioside fraction using thin-layer chromatogram immunostaining. Antibody activity was detected against a band that migrated just below GDla in 6 of the 50 patients with GBS tested. Antibody titer, as determined by enzyme-linked immunosorbent assay, decreased during the course of the disease. All 6 patients had suffered gastrointestinal infection before the neurological onset of GBS and showed low

📜 SIMILAR VOLUMES

The First Total Synthesis of Ganglioside
The First Total Synthesis of Ganglioside GalNAc-GD1a, a Target Molecule for Autoantibodies in Guillain–Barré Syndrome
✍ Dr. Kohki Fujikawa; Shinya Nakashima; Miku Konishi; Tomoaki Fuse; Naoko Komura; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 1 views

## Abstract The first synthesis of ganglioside GalNAc‐GD1a, featuring efficient glycan assembly and a cyclic glucosyl ceramide as a versatile unit for ganglioside synthesis is described. Although ganglioside GalNAc‐GD1a was first found as a brain ganglioside, IgG autoantibodies to GalNAc‐GD1a were